Study demonstrates CV safety of Trajenta, including heart failure (Ref. 1)

esults from the CARMELINA® Study (CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin) published in the Journal of the American Medical Association (JAMA) provide important evidence of the safety of Trajenta (linagliptin) in patients with type 2 diabetes with high cardiovascular and/or renal risk.1


The study demonstrates that using this DPP-4 inhibitor in a broad group of high-risk patients with type 2 diabetes provides not only efficacious glucose-lowering, but also